Pro Medicus Limited (ASX:PME)
Australia · Delayed Price · Currency is AUD | Market Cap | 14.43B -31.8% |
| Revenue (ttm) | 240.57M +30.3% |
| Net Income | 234.70M +138.8% |
| EPS | 2.24 +138.7% |
| Shares Out | 104.47M |
| PE Ratio | 61.59 |
| Forward PE | 82.02 |
| Dividend | 0.64 (0.46%) |
| Ex-Dividend Date | Feb 26, 2026 |
| Volume | 169,819 |
| Average Volume | 337,001 |
| Open | 137.50 |
| Previous Close | 138.12 |
| Day's Range | 135.80 - 138.98 |
| 52-Week Range | 107.75 - 336.00 |
| Beta | 0.56 |
| RSI | 51.40 |
| Earnings Date | May 13, 2026 |
About Pro Medicus
Pro Medicus Limited, a healthcare informatics company, engages in the development and supply of healthcare imaging software, and radiology information (RIS) system software and services to hospitals, imaging centers, and health care groups in Australia, North America, and Europe. The company offers Visage RIS Visage 7 Enterprise Imaging Platform, a healthcare imaging software that provides radiologists, physicians, and clinicians with access and visualization capability for viewing 2-D, 3-D, and 4-D medical images; and picture archive and commu... [Read more]
Financial Performance
In fiscal year 2025, Pro Medicus's revenue was 212.98 million, an increase of 31.88% compared to the previous year's 161.50 million. Earnings were 115.22 million, an increase of 39.16%.
Financial StatementsNews
Pro Medicus Earnings Call Transcript: H1 2026
Revenue and EBIT grew over 28% year-over-year, driven by record contract wins and expanding cloud-native, full-stack solutions. Major deals in cardiology and pathology, a robust pipeline, and strong margin performance set the stage for accelerated growth in the second half and beyond.
Pro Medicus Transcript: AGM 2025
Record financial results and strong contract wins drove growth, with expanded dividends and a robust pipeline. Strategic investments, new product offerings, and ambitious targets for the next three years were highlighted, while all AGM resolutions passed with strong shareholder support.
Pro Medicus Earnings Call Transcript: H2 2025
Record FY25 with revenue up 32%, profit after tax up 40%, and margins at 74%. Secured $520M in new contracts, expanded into cardiology and digital pathology, and maintained 100% renewal rate. Cloud and AI offerings drive competitive advantage.
Pro Medicus Earnings Call Transcript: H1 2025
Record first-half results with 31% revenue and 43% profit growth, driven by major new contracts, renewals, and expanding U.S. market share. Margins remain strong, pipeline replenishment is robust, and cloud-based innovation and AI position the business for continued growth.
Pro Medicus Transcript: AGM 2024
Record financial results, major contract wins, and increased dividends highlighted a strong year. Strategic focus remains on the U.S. market, AI, and cloud innovation, with robust governance and high shareholder support for all resolutions.
Pro Medicus Earnings Call Transcript: H2 2024
Revenue and profit after tax rose 29.3% and 36.5% year-over-year, driven by record new sales, cloud-based contract wins, and strong North American growth. Margins improved, pipeline remains robust, and the company is expanding into AI and cardiology, with no contract losses reported.